<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349008</url>
  </required_header>
  <id_info>
    <org_study_id>Cttq-MAGIC-101</org_study_id>
    <nct_id>NCT03349008</nct_id>
  </id_info>
  <brief_title>Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B</brief_title>
  <acronym>MAGIC-101</acronym>
  <official_title>The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cttq</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients
      with chronic hepatitis B in China. Half of participants will receive magnesium
      isoglycyrrhizinate followed by oral diammonium glycyrrhizinate and entecavir in combination,
      while the other half will receive a placebo and entecavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B(HBV) has a high prevalence (&gt;8%) in China. Entecavir, aguanosine analog,
      is a potent and selective inhibitor of HBV DNA polymerase.

      Glycyrrhizin has been used for more than 30 years in the treatment of liver diseases in Asian
      countries, who can relieve necro-inflammatory and liver fibrosis or cirrhosis Recent study
      has shown that inflammation plays the important role in chronic HBV and fibrosis or cirrhosis
      disease progression, but antiviral therapy only may not reduce inflammation ideally. The
      addition of glycyrrhizin to entecavir in the treatment may slow disease progression in
      patients with chronic HBV and advanced fibrosis or cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 25, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of ALT(Alanine aminotransferase)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>The ALT levels of plasma are measured at baseline and at 24 weeks. The normal value was 0-40 U/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Liver inflammatory</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Liver inflammatory of the liver biopsies is performed at baseline and 24 weeks evaluated by Knodell HAI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Liver Fibrosis</measure>
    <time_frame>baseline and 96 weeks</time_frame>
    <description>Liver Fibrosis is performed at baseline and 96 weeks evaluated by Fibroscan examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <condition>Liver Inflammation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Entecavir Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Isoglycyrrhizinate</intervention_name>
    <description>Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Magnesium Isoglycyrrhizinate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diammonium Glycyrrhizinate</intervention_name>
    <description>Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Diammonium Glycyrrhizinate Enteric-coated Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Isoglycyrrhizinate Placebo</intervention_name>
    <description>Magnesium Isoglycyrrhizinate Injection Placebo</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Magnesium Isoglycyrrhizinate Injection Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diammonium Glycyrrhizinate Placebo</intervention_name>
    <description>Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatitis B surface antigen [HBsAg]-positive,

          -  Either hepatitis B e antigen (HBeAg)-positive or HBeAgnegative/hepatitis B e antibody
             (HBeAb)-positive disease were eligible,

          -  Serum alanine aminotransferase (ALT) levels 3-10×the upper limit of normal (ULN),serum
             total bilirubin(TBIL)levels&lt;2×ULN

        Exclusion Criteria:

          -  Co-infection with hepatitis C virus, hepatitis D virus, or human immunodeficiency
             virus;

          -  Other forms of liver disease;

          -  More than 24 weeks of therapy with a nucleoside or nucleotide analog with activity
             against HBV, and therapy with any anti-HBV drug within 24 weeks prior to
             randomization;

          -  More than 12 weeks of therapy with liver protectants, and therapy with glycyrrhizin;

          -  Has decompensated liver function or has a hint of hepatocellular carcinoma (HCC);

          -  During the study patients were not allowed to use other medicines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>necro-inflammatory</keyword>
  <keyword>glycyrrhizin</keyword>
  <keyword>entecavir</keyword>
  <keyword>hepatic biological parameters</keyword>
  <keyword>liver fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Glycyrrhizic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

